Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is in a solid financial position with a strong cash balance, manageable debt, and the ability to continue making debt repayments ahead of schedule. As one of the leaders in digital healthcare technology, OptimizeRx is well-positioned to take advantage of the increasing shift towards digital interactions between pharma companies and healthcare providers. However, the company's reliance on a few large clients and potential risk from generic drugs could impact its operations and financials. Despite some short-term challenges, OptimizeRx has strong growth potential in the long-term thanks to its innovative products and expanded customer base.

Bears say

OptimizeRx is a digital healthcare technology company with strong financial results. However, factors such as industry changes, competition, and potential difficulties with adoption and integration could impede their growth plan. Additionally, their small size and limited resources could make it challenging to sustain positive cash flow and pursue aggressive sales and marketing efforts. Overall, these factors lead to a negative outlook on the company's stock.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.